SAM #RRPV-RPP-26-10-RAPID

BARDA Solicitation for Rapid Antigen Production Platforms for Immunoassay Diagnostics

BARDA, part of HHS, is soliciting advanced research and development services for rapid antibody and protein-based reagent generation platforms for immunoassay diagnostics. - Issued through the Rapid Response Partnership Vehicle (RRPV) Consortium - Seeks flexible, end-to-end systems for rapid production of immunoassay-ready reagents - Focus on platforms that compress timelines from pathogen sequence to assay-ready reagents within weeks - Goal: Generate high-performance molecular binders for diagnostics against known and emerging biological threats - No specific OEMs, products, part numbers, or purchase quantities listed - Emphasis on innovative R&D capabilities and rapid response to biological threats - Place of performance and contracting office: O’NEILL HOUSE OFFICE BUILDING, Washington, DC

Key Requirements: - Ability to rapidly produce diagnostic reagents for new and existing biological threats - Flexible platforms suitable for end-to-end reagent generation - Timely delivery of assay-ready binders

Opportunity Type: - Research and development solicitation (not a product purchase) - No specific product or service line items beyond advanced R&D services

Description

This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority  (BARDA) entitiled "Rapid Antigen Production for Immunoassay Diagnostics (RAPID)".

Through the Rapid Antibody Production for Immunoassay Diagnostics (RAPID) RPP, BARDA seeks to support advanced research and development of rapid antibody and other protein-based molecular recognition reagent generation platforms to enable timely production of immunoassay-ready reagents for diagnostic use. The objective is to establish flexible, end-to-end systems capable of generating high-performance binders against known and emerging biological threats, with the goal of significantly compressing development timelines from pathogen sequence to assay-ready reagents—ideally within weeks.

A Proposer’s Conference and Teaming Connect for the Rapid Antibody Production for Immunoassay Diagnostics (RAPID) RPP will take place virtually on Monday, April 27, 2026 from 11am-12pm EST.

The full RPP, how to register for the Conference, and information on joining the consortium can be accessed through the RRPV website - www.rrpv.org.  

Additional Links:Solicitation Site

View original listing